Targeting PD-1 with therapeutic immunotherapy in preclinical models of NASH-induced HCC increased the number of activated CD8+ PD-1+ T cells inside tumors; however, it did not cause tumor regression, indicating that tumor immune surveillance was compromised [16]. This evidence concerns the gene CD8A and metabolic dysfunction-associated steatohepatitis.